NASDAQ · SLXNW

Silexion Therapeutics Corp.

$0.05 -$0.00 (-7.00%) 1D Market open

Key Metrics

$21.02K
Market cap
P/E · TTM
Revenue · TTM
−$998.00K
Net income
EPS · TTM $-2.21
Dividend yield
Free cash flow
Beta · 1Y 3.13
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    The stock moved +98.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 17
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 22
    The stock moved +76.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 22
  • May 18
    From its Feb 2 high, the share price fell 75%.

    Peak close $0.04 on Feb 2; trough close $0.01 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -75%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.01 – $0.15
Avg volume · 20D61.2K
Net cash
Book value / share$0.64
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Silexion Therapeutics Corp.
IPO dateAug 16, 2024
Employees13

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS).

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 54.0% · —

Financial Health

Current ratio1.00
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.00K

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings